Yesterday, Oct. 2, 2015, 57 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $329.66 to $5,418,750.00.

Highlighted Stocks Traded by Insiders:

Willamette Valley Vineyards (WVVI) - FREE Research Report

Sarles Christopher L, who is Director at Willamette Valley Vineyards, bought 1,205 shares at $4.15 on Oct. 2, 2015. Following this transaction, the Director owned 1,205 shares meaning that the stake was boosted by 100% with the 1,205-share transaction.

The shares most recently traded at $6.73, up $2.58, or 38.34% since the insider transaction. Historical insider transactions for Willamette Valley Vineyards go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 4,275
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 5,275
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 5,275

The average volume for Willamette Valley Vineyards has been 13,000 shares per day over the past 30 days. Willamette Valley Vineyards has a market cap of $33.2 million and is part of the consumer goods sector and food & beverage industry. Shares are up 16.38% year-to-date as of the close of trading on Thursday.

Willamette Valley Vineyards, Inc. produces and sells wines in the United States and internationally. The company has a P/E ratio of 14.5.

Exclusive Offer: Get the latest Stock Analysis on WVVI - FREE

TheStreet Quant Ratings

rates Willamette Valley Vineyards as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Willamette Valley Vineyards Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Skullcandy (SKUL) - FREE Research Report

Ptarmagin, Llc, who is 10% Owner at Skullcandy, sold 37,500 shares at $5.55 on Oct. 2, 2015. Following this transaction, the 10% Owner owned 5.0 million shares meaning that the stake was reduced by 0.74% with the 37,500-share transaction.

The shares most recently traded at $5.80, up $0.25, or 4.31% since the insider transaction. Historical insider transactions for Skullcandy go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 137,500
  • 12-Week # shares bought: 17,000
  • 12-Week # shares sold: 137,500
  • 24-Week # shares bought: 17,000
  • 24-Week # shares sold: 137,500

The average volume for Skullcandy has been 179,200 shares per day over the past 30 days. Skullcandy has a market cap of $158.9 million and is part of the consumer goods sector and consumer durables industry. Shares are down 38.08% year-to-date as of the close of trading on Friday.

Skullcandy Inc. designs, markets, and distributes audio and gaming headphones, earbuds, speakers, and other accessories under the Skullcandy, Astro Gaming, and 2XL brands in the United States and internationally. The company has a P/E ratio of 22.4. Currently, there are 5 analysts who rate Skullcandy a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SKUL - FREE

TheStreet Quant Ratings

rates Skullcandy as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, unimpressive growth in net income and weak operating cash flow. Get the full

Skullcandy Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AMAG Pharmaceuticals (AMAG) - FREE Research Report

Heiden William K, who is Ceo at AMAG Pharmaceuticals, sold 2,000 shares at $39.69 on Oct. 2, 2015. Following this transaction, the Ceo owned 200,721 shares meaning that the stake was reduced by 0.99% with the 2,000-share transaction.

The shares most recently traded at $41.30, up $1.61, or 3.9% since the insider transaction. Historical insider transactions for AMAG Pharmaceuticals go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 4,000
  • 24-Week # shares sold: 62,125

The average volume for AMAG Pharmaceuticals has been 1.0 million shares per day over the past 30 days. AMAG Pharmaceuticals has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are down 1.17% year-to-date as of the close of trading on Friday.

AMAG Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that focuses on maternal health, anemia, and cancer supportive care. The company has a P/E ratio of 5.5. Currently, there are 5 analysts who rate AMAG Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMAG - FREE

TheStreet Quant Ratings

rates AMAG Pharmaceuticals as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

AMAG Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.